Previous 10 | Next 10 |
home / stock / alpmf / alpmf news
2023-08-16 12:41:31 ET Summary Astellas has closed its Iveric bio, Inc. deal in July and reported JPY 375Bn in quarterly sales in Q1. The company's earnings power and asset factors are bullish, but valuation factors are keeping me neutral. From this, I am closely watching the ...
2023-08-14 07:55:03 ET Summary George Soros's 13F portfolio value decreased slightly from $6.49B to $6.41B, with 172 positions. New stakes include PDC Energy, IVERIC bio, ARK Innovation ETF Calls, Alibaba Group Holding, Five9 Puts, RenaissanceRE Holdings, and MicroStrategy Puts. ...
2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...
2023-08-07 13:54:42 ET More on Apellis Apellis: Exercise Caution In Response To Safety Signal (Rating Downgrade) Apellis Pharmaceuticals: Biotech's Rising Star In C3 Inhibition Space Apellis extends selloff as JPMorgan becomes latest to downgrade Apellis off ...
2023-08-07 11:25:39 ET More on Poseida Poseida Therapeutics: Pioneering Cell And Gene Therapies Spark Excitement And Caution Poseida gains on FDA nod to start trials for CAR-T therapy Poseida stock falls ~8% postmarket after founder, executive chairman to step down ...
2023-08-06 22:42:08 ET Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Conference Call August 01, 2023, 04:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Naoki Okamura - Representative Director, President and CEO Yoshitsugu S...
2023-08-01 08:05:53 ET Astellas Pharma press release ( OTCPK:ALPMF ): Q1 GAAP EPS of ¥28.88. Revenue of ¥374.99B (-1.8% Y/Y). For further details see: Astellas Pharma GAAP EPS of ¥28.88, revenue of ¥374.99B
2023-07-21 19:02:28 ET Summary Merck & Co., Inc. has increased reliance on Keytruda and Gardasil. Merck became a Seeking Alpha Quant system Strong Buy on July 11 for no clear reason. Clinical catalysts have so far not moved Merck stock upward. Our previous cove...
2023-06-18 07:05:00 ET Summary San Diego-Shanghai company Cullgen will collaborate with Japan's Astellas Pharma to discover multiple innovative protein degraders in a deal worth up to $1.9 billion. Cholesgen (Shanghai) formed a three-year collaboration with AstraZeneca to develop ...
2023-05-30 15:02:46 ET Summary Iveric bio, Inc., focused on developing treatments for retinal diseases, has announced its acquisition by Astellas Pharma Inc. Iveric bio, Inc. stock trades at a discount of over 5% for an acquisition that is targeted to close in the third calendar q...
News, Short Squeeze, Breakout and More Instantly...
Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...
One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca 's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive...
This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ...